Dosage evidence

Ipamorelin Dosage: Why There Is No Established Dose

The only peptide here still sitting in FDA's category 2 list, under the 503B interim policy — added September 29, 2023 and still listed as of the page's April 2026 revision.

Where Ipamorelin stands with the FDA

FDA category 2 — 503B compounding
A study published in literature identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility.
— US Food and Drug Administration, verbatim

There is no dose to report

No FDA-labeled dose exists, and we found no published human dosing we were willing to present as a protocol. FDA states it lacks sufficient information to know whether ipamorelin would cause harm via several injectable routes.

We would rather tell you this than publish a number. Pages that rank for “ipamorelin dosage” routinely state precise-looking figures with no citation attached to them. A number without a source is not more useful than an honest absence — it is less useful, because it looks like it came from somewhere.

Convert your prescribed dose to syringe units

If a clinician has prescribed Ipamorelin for you, the number that matters next is how far to draw the syringe — and that depends on how much bacteriostatic water went into the vial, not on the peptide itself.

What this does — and what it does not

This converts a dose your prescriber has already given you into a volume and a number of units on a U-100 insulin syringe. It does not suggest a dose, and it does not tell you whether a peptide is appropriate for you. Most research peptides have no FDA-approved dosing, so there is no “standard” number for us to fill in. Doses here are in micrograms (mcg) — confusing mcg with mg is a 1,000-fold error and the single most common way people get this wrong.

Enter the dose your prescriber gave you, in micrograms, to see the volume and syringe units.

Your 5 mg vial in 2 mL of bacteriostatic water is .

Keep reading

References

  1. 1.US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — category 2 of the interim policies, and the list of substances nominated but withdrawn. FDA Human Drug Compounding. 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

This page reports what regulators and published sources say about Ipamorelin. It is not medical advice, not a recommendation to use Ipamorelin, and not a dosing instruction. Every source above was opened and read on the date recorded in our data; regulatory status changes, so check the primary source before relying on it.